Investors 'unhappy' over drug firm's performance

Major investors in British drug delivery firm SkyePharma were today said to be considering a campaign to force its chairman to stand down.

Shareholders such as Fidelity and Insight Investment Management were reported to be unhappy about the performance of £362m-valued SkyePharma, which has received an approach about a merger from a company a third of its size.